Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 5/20 | 0.58 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.58 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | DRD4 | P21917 | 3/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.45 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20374733 | 0.94 | GNAO1 (0.60) | GNAO1GNAI3GNAI1HRH3CYP1A2 | |
| SCHEMBL24207822 | 0.88 | GNAO1 (0.53) | GNAO1GNAI3GNAI1HRH3CHRM1 | |
| SCHEMBL5197870 | 0.86 | GNAO1 (0.54) | GNAO1GNAI3GNAI1HRH3CYP1A2 | |
| SCHEMBL7558440 | 0.85 | GNAO1 (0.55) | GNAO1GNAI3GNAI1HRH3CHRM1 | |
| SCHEMBL6059146 | 0.85 | GNAO1 (0.54) | GNAO1GNAI3GNAI1HRH3CHRM1 | |
| SCHEMBL12561560 | 0.85 | GNAO1 (0.50) | GNAO1GNAI3GNAI1HRH3CYP1A2 | |
| SCHEMBL9823958 | 0.83 | GNAO1 (0.47) | GNAO1GNAI3GNAI1HRH3CHRM1 | |
| SCHEMBL9824478 | 0.82 | GNAO1 (0.46) | GNAO1GNAI3GNAI1HRH3CHRM1 | |
| SCHEMBL17424060 | 0.82 | GNAO1 (0.59) | GNAO1GNAI3GNAI1HRH3CYP1A2 | |
| SCHEMBL11410375 | 0.81 | ALOX15 (0.55) | GNAO1GNAI3GNAI1CHRM1PRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278741-B1 | MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-03-02 | — | — | EP | claimed |
| EP-2445877-B1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS INC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2445877-B1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS INC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2445877-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Nanotherapeutics, Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120088793-A1 | Bicyclic Compounds and Methods of Making and Using Same | NANOTHERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120088793-A1 | Bicyclic Compounds and Methods of Making and Using Same | NANOTHERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120088793-A1 | Bicyclic Compounds and Methods of Making and Using Same | NANOTHERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8114894-B2 | Bicyclic compounds and methods of making and using same | NANOTHERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114894-B2 | Bicyclic compounds and methods of making and using same | NANOTHERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114894-B2 | Bicyclic compounds and methods of making and using same | NANOTHERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| CN-1814596-A | Muscarinic agonists | ARCADIA PHARMACEUTICALS INC (US) | 2006-08-09 | — | — | CN | disclosed |
| CN-1249051-C | Muscarinic agonists | ACADIA PHARM INC (US) | 2006-04-05 | — | — | CN | disclosed |
| EP-1535912-A1 | Muscarinic agonists | Arcadia Pharmaceuticals Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113357-A1 | Muscarinic agonists | ANDERSON CARL-MAGNUS A (DK) | 2005-05-26 | — | — | US | disclosed |
| EP-1278741-B1 | MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6627645-B2 | Cholinergic agents | ACADIA PHARMACEUTICALS, INC. | 2003-09-30 | — | — | US | disclosed |
| CN-1439002-A | Muscarinic agonists | ACADIA PHARM INC (US) | 2003-08-27 | — | — | CN | disclosed |
| EP-1278741-A1 | MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2001083472-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088793-A1 | Bicyclic Compounds and Methods of Making and Using Same | HTR2C, HTR3A, HTR3C | GNAO1 301/4885GNAI3 886/4885GNAI1 1022/4885 |
| US-20020037886-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | GNAO1 303/4885GNAI3 1568/4885GNAI1 1313/4885 |
| US-20050113357-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | GNAO1 303/4885GNAI3 1568/4885GNAI1 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.